{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:26:35Z","timestamp":1790011595208,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40291-021-00555-1","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T14:06:06Z","timestamp":1629727566000},"page":"803-809","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Elivaldogene Autotemcel: First Approval"],"prefix":"10.1007","volume":"25","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"555_CR1","unstructured":"bluebird bio. Our science: what is gene therapy? 2021. https:\/\/www.bluebirdbio.com\/our-science\/what-is-gene-therapy. Accessed 19 July 2021."},{"key":"555_CR2","unstructured":"European Medicines Agency. Skysona (elivaldogene autotemcel): EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/. Accessed 26 July 2021."},{"key":"555_CR3","unstructured":"bluebird bio. Fom 10-K. 2021. https:\/\/investor.bluebirdbio.com\/static-files\/a0cfdff2-2784-4e01-9237-8be586e10bce. Accessed 7 July 2021."},{"issue":"7","key":"555_CR4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s10072-021-05412-x","volume":"42","author":"A Federico","year":"2021","unstructured":"Federico A, de Visser M. New disease modifying therapies for two genetic childhood-onset neurometabolic disorders (metachromatic leucodystrophy and adrenoleucodystrophy). Neurol Sci. 2021;42(7):2603\u20136.","journal-title":"Neurol Sci"},{"key":"555_CR5","unstructured":"Musolino P, Lauer A, Choi M, et al. Lenti-D gene therapy attenuates microvascular perfusion abnormalities and halts cerebral adrenoleukodystrophy lesion progression [abstract no. 156]. Ann Neurol. 2019;86(Suppl 23):S113\u20134."},{"key":"555_CR6","unstructured":"European Medicines Agency. First gene therapy to treat children with rare inherited neurological disease [media release]. 21 May 2021. http:\/\/www.ema.europa.eu."},{"key":"555_CR7","unstructured":"European Network for Health Technology Assessment (EUnetHTA), Agency for Health Technology Assessment and Tariff System (AOTMiT), Gesundheit \u00d6sterreich GmbH (G\u00d6G). Elivaldogene autotemcel (eli-cel) for treatment of cerebral adrenoleukodystrophy (CALD)\u2014project plan. Version 1, 25 May 2021. 2021. https:\/\/www.eunethta.eu\/wp-content\/uploads\/2021\/05\/PTJA17-Eli-cel-Project-Plan-v1.0.pdf. Accessed 19 July 2021."},{"issue":"6","key":"555_CR8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jamaneurol.2017.0095","volume":"74","author":"K Van Haren","year":"2017","unstructured":"Van Haren K, Engelen M. Decision making in adrenoleukodystrophy: when is a good outcome really a good outcome? JAMA Neurol. 2017;74(6):641\u20132.","journal-title":"JAMA Neurol"},{"issue":"17","key":"555_CR9","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","volume":"377","author":"F Eichler","year":"2017","unstructured":"Eichler F, Duncan C, Musolino PL, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377(17):1630\u20138.","journal-title":"N Engl J Med"},{"key":"555_CR10","unstructured":"bluebird bio. bluebird bio receives EC approval for SKYSONA\u2122 (elivaldogene autotemcel, Lenti-D\u2122) gene therapy for patients less than 18 years of age with early cerebral adrenoleukodystrophy (CALD) without matched sibling donor [media release]. 21 Jul 2021. https:\/\/investor.bluebirdbio.com\/."},{"key":"555_CR11","unstructured":"K\u00fchl J-S, Duncan C, Eichler F, et al. Elivaldogene autotemcel (eli-cel; Lenti-D) gene therapy for cerebral adrenoleukodystrophy: updated results from the phase 2\/3 study and safety outcomes report from the phase 3 study [abstract no. GS2-8]. 47th annual meeting of the EBMT 14\u201317 March 2021 Virtual. 2021."},{"key":"555_CR12","unstructured":"bluebird bio. bluebird bio and apceth Biopharma establish commercial drug product manufacturing agreement [media release]. 15 Dec 2016. http:\/\/www.bluebirdbio.com."},{"key":"555_CR13","unstructured":"Lonza Houston Inc. Lonza and bluebird bio, Inc., establish a long-term commercial manufacturing agreement for Lenti-DTM and LentiGlobinTM drug products [media release]. 9 Jun 2016. http:\/\/www.lonza.com."},{"key":"555_CR14","unstructured":"bluebird bio, G\u00e9n\u00e9thon. bluebird bio and G\u00e9n\u00e9thon announce manufacturing research collaboration centered on lentiviral vectors for gene therapy [media release]. 15 Dec 2010. http:\/\/www.bluebirdbio.com."},{"key":"555_CR15","unstructured":"Genetix Pharmaceuticals Inc. Genetix Pharmaceuticals announces global clinical plans to treat adrenoleukodystrophy [media release]. 7 Nov 2009. http:\/\/www.genetixpharm.com."},{"key":"555_CR16","doi-asserted-by":"publisher","unstructured":"Bougneres P, Hacein-Bey-Abina S, Labik I, et al. Long-term follow-up of hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. Hum Gene Ther. 2021. https:\/\/doi.org\/10.1089\/hum.2021.053.","DOI":"10.1089\/hum.2021.053"},{"issue":"5954","key":"555_CR17","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.1171242","volume":"326","author":"N Cartier","year":"2009","unstructured":"Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326(5954):818\u201323.","journal-title":"Science"},{"key":"555_CR18","first-page":"75","volume":"55","author":"E Yannaki","year":"2020","unstructured":"Yannaki E, Locatelli F, Thrasher AJ, et al. Safety of autologous hematopoietic stem cell transplantation with gene addition therapy for transfusion-dependent beta-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy [abstract no. O065]. Bone Marrow Transplant. 2020;55:75\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"555_CR19","unstructured":"bluebird bio. bluebird bio reports second quarter financial results and provides operational update [media release]. 9 Aug 2021. https:\/\/investor.bluebirdbio.com\/."}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-021-00555-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-021-00555-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-021-00555-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T21:22:28Z","timestamp":1638048148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-021-00555-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1007\/s40291-021-00555-1","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]},"assertion":[{"value":"13 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan Keam is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability"}}]}}